Novocure Announces Topline Data from the Phase 3 TRIDENT Trial Evaluating Earlier Use of Tumor Treating Fields Therapy in Newly Diagnosed Glioblastoma
Go back to Novocure Announces Topline Data from the Phase 3 TRIDENT Trial Evaluating Earlier Use of Tumor Treating Fields Therapy in Newly Diagnosed Glioblastoma| (NASDAQ: NVCR) | Delayed: 13.96 +0.35 (2.57%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $13.61 | 52 Week High | $28.95 | |||
| Open | $13.43 | 52 Week Low | $5.95 | |||
| Day High | $14.24 | P/E | N/A | |||
| Day Low | $13.43 | EPS | $0.00 | |||
| Volume | 876,030 | |||||
